Hoth Therapeutics Inc HOTH

NAS: HOTH | ISIN: US44148G1058   8/05/2024
1,210 USD (+1,68%)
(+1,68%)   8/05/2024

1 mei 2024 · Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 · Persbericht

27 maart 2024 · Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds · Persbericht

27 maart 2024 · Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment · Persbericht

19 maart 2024 · Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ · Persbericht

29 februari 2024 · Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio · Persbericht

26 februari 2024 · Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic · Persbericht

13 februari 2024 · Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 · Persbericht

18 januari 2024 · Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients · Persbericht

27 december 2023 · Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami · Persbericht

5 december 2023 · Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies · Persbericht

10 november 2023 · Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023 · Persbericht

5 oktober 2023 · Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery · Persbericht

2 oktober 2023 · FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients · Persbericht

15 september 2023 · Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules · Persbericht

13 september 2023 · Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules · Persbericht

13 september 2023 · Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia · Persbericht

11 september 2023 · Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients · Persbericht

6 september 2023 · Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa · Persbericht

9 augustus 2023 · Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease · Persbericht

25 juli 2023 · Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial · Persbericht

Mijn selecties